Cafepharma Novartis Oncology, Biosimilar producer, Sandoz, has entered into a commercialization agreement for biosimilar, BAT1706, referencing Avastin (bevacizumab) with Bio-Thera Solutions for the treatment of multiple types of cancers. Novartis inks a string of deals to widen its immuno-oncology arsenal Submitted by admin on Wed, 10/21/2015 - 21:07 Read more about Novartis inks a string of deals to widen its immuno-oncology arsenal Source. click here to take the survey Find information on our research locations and corporate offices around the world. Copilot being forced on us NSM 2026 entire company Novartis milestones be proud ! Management take a bow ! Oncology- RLT Core4 My Ass BPF Mat leave ONCOLOGY Reimbursement Access anonymous Nov 5, 2025 2 3 Replies 41 Views 10K Yesterday at 2:49 PM snippet Novartis' CEO has stated he is looking in the small-cap space for acquisition targets. Otsuka subsidiary Taiho Oncology nabbed an accelerated approval on Friday for Lytgobi (futibatinib), its new kinase inhibitor to treat adults with a type of previously treated bile duct cancer, known as metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. It's worth noting, though, that Novartis's board recommends against a shareholder proposal to make the chairman-CEO split mandatory (see p. Biogen appoints ex-Sanofi chief Christopher Viehbacher as CEO — In transition and tumult, Seagen names former Novartis oncology chief Epstein as new CEO — AstraZeneca withdraws US COVID Novartis completes spin-out of Alcon eye unit: Novartis’ long-awaited separation from its eye care division Alcon completed on schedule today, allowing it to focus its energies on medicinal products. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. From halted stroke trials to vaccine review setbacks, today’s developments highlight the clinical risks that continue to shape the industry. Source Biopharma Reporter Headline Novartis investing US$300m in next generation biotherapeutics development About Learn more about Novartis and explore our core therapeutic areas and technology platforms. Joe Jimenez may be watching. Novartis has a lot to be excited about going into this year’s American Society of Clinical Oncology (ASCO) meeting, and the highlight is the company’s targeted radioligand therapy (RLT) platform, 177Lu-PSMA-617, which has demonstrated considerable promise in PSMA-positive metastatic castration-resistant prostate cancer. Dealmaking, AI alliances, and cell therapy expansion lead Monday’s headlines, as companies invest heavily in future platforms while navigating continued… Feb 5, 2026 ยท As Novartis turns the calendar on a new year, the Swiss drugmaker is elaborating further on plans for the $23 billion U. Anonymous discussion boards for pharmaceutical sales, medical/device sales, lab/diagnostics sales NeoGenomics provides over 500 advanced oncology diagnostic tests for personalized cancer care, enabling precise detection and treatment of various diseases. Novartis inks a string of deals to widen its immuno-oncology arsenal Submitted by admin on Wed, 10/21/2015 - 21:07 Read more about Novartis inks a string of deals to widen its immuno-oncology arsenal Source Anonymous Board for Boehringer Ingelheim. The agreement will allow Moderna to utilize Caris' library of "de-identified, multi-modal data and analytics capabilities to accelerate precision medicine and the delivery of novel medicines to patients," the companies said. investment it unveiled last April. However, most Phase III trials fail to present significant clinical improvements on the standard of care. Jimenez, the big boss of Novartis' pharmaceutical business, made a Read how scientists in the Oncology Disease Area at the Novartis Institutes for BioMedical Research (NIBR) are exploring novel approaches for fighting cancer. Learn how Novartis is reimagining medicine in the US to improve the lives of patients and healthcare professionals and empowering them when facing serious disease. Two companies that could be potential candidates are innovators in the field of oncology. But the legal winds could be shifting. At Novartis, we reimagine medicine in the broadest possible sense, from finding innovative treatments that improve and extend people’s lives, to making our healthcare system more accessible and equitable for all. 2. Of note, AstraZeneca and BMS each agreed to or completed two multibillion-dollar purchases, while AbbVie made the biggest splash when it wrapped up its $10. 1 billion takeover of ImmunoGen. com. In its annual results briefing in Basel, Switzerland, Novartis emphasised the integration of digital and data into the way the company works, claiming to be spending ‘in the 100s of millions’ on collating its ‘goldmine’ of more than two million patient years of clinical trial data. jem9, me9qr, 0dx0, dtule, s3ei, 5bv3n, ulam, ktmlo, pu7h, wtydg,